<DOC>
	<DOCNO>NCT01187433</DOCNO>
	<brief_summary>The purpose study generate immunogenicity safety data preparation efficacy study Latin America . Primary Objectives : - To describe immune response dengue virus vaccination CYD dengue vaccine . - To evaluate safety vaccination CYD dengue vaccine .</brief_summary>
	<brief_title>Study CYD Dengue Vaccine Healthy Children Adolescents South America</brief_title>
	<detailed_description>Participants Dengue Vaccine Group receive 3 vaccination CYD Dengue vaccine . Participants Control Group receive placebo vaccination first 2 vaccination , follow tetanus toxoid , reduce diphtheria toxoid , acellular pertussis vaccine adsorb ( ADACEL® ) ( Venezuela ) Meningococcal A+C vaccine ( Brazil ) way provide therapeutic benefit participant control group .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 9 16 year day inclusion Participant good health , base medical history physical examination Provision assent form/informed consent form sign participant parent ( ) another legally acceptable representative Participant parent ( ) /legally acceptable representative ( ) able attend schedule visit comply trial procedure For female participant childbearing potential , avoid become pregnant ( use effective method contraception abstinence ) least 4 week prior first vaccination least 4 week last vaccination Exclusion Criteria : Personal family history thymic pathology ( thymoma ) , thymectomy , myasthenia For female participant childbearing potential , known pregnancy positive urine pregnancy test Visit 1 Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Breastfeeding woman Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Known systemic hypersensitivity component trial vaccine history lifethreatening reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion , opinion Investigator Current alcohol abuse drug addiction may interfere participant 's ability comply trial procedure Receipt blood bloodderived product precede 3 month might interfere assessment immune response Receipt vaccine 4 week precede first trial vaccination Planned receipt vaccine 4 week follow first trial vaccination Participant deprive freedom administrative court order , emergency setting , hospitalize without his/her consent Febrile illness ( temperature ≥ 38.0 ºC ) moderate severe acute illness/infection day vaccination , accord Investigator judgment Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular vaccination Severe diseases without fever , convulsion neurological abnormality without treatment progression .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dengue</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>CYD Dengue Vaccines</keyword>
</DOC>